Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Fisher Asset Management LLC

Fisher Asset Management LLC trimmed its position in shares of Gilead Sciences, Inc. (NASDAQ:GILDGet Rating) by 22.8% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,368 shares of the biopharmaceutical company’s stock after selling 1,884 shares during the period. Fisher Asset Management LLC’s holdings in Gilead Sciences were worth $379,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in GILD. OmniStar Financial Group Inc. boosted its holdings in Gilead Sciences by 49.9% in the first quarter. OmniStar Financial Group Inc. now owns 20,110 shares of the biopharmaceutical company’s stock valued at $1,195,000 after purchasing an additional 6,698 shares in the last quarter. Royce & Associates LP acquired a new position in Gilead Sciences in the first quarter valued at approximately $1,308,000. HealthInvest Partners AB acquired a new position in Gilead Sciences in the first quarter valued at approximately $5,826,000. TrueWealth Advisors LLC acquired a new position in Gilead Sciences in the first quarter valued at approximately $213,000. Finally, MCF Advisors LLC acquired a new position in Gilead Sciences in the first quarter valued at approximately $247,000. 80.16% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. Piper Sandler lowered their price target on Gilead Sciences from $73.00 to $69.00 and set a “neutral” rating for the company in a report on Monday, May 16th. Royal Bank of Canada increased their price objective on Gilead Sciences from $76.00 to $77.00 and gave the company an “outperform” rating in a report on Tuesday, April 12th. Morgan Stanley increased their price objective on Gilead Sciences from $63.00 to $65.00 and gave the company an “equal weight” rating in a report on Friday, July 15th. SVB Leerink initiated coverage on Gilead Sciences in a report on Monday, May 23rd. They issued a “market perform” rating and a $68.00 price objective for the company. Finally, TheStreet downgraded Gilead Sciences from a “b-” rating to a “c+” rating in a report on Friday, July 1st. One research analyst has rated the stock with a sell rating, nine have given a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $72.07.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $61.09 on Friday. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.49 and a quick ratio of 1.30. The stock has a fifty day moving average price of $61.55 and a 200 day moving average price of $61.93. Gilead Sciences, Inc. has a 1-year low of $57.17 and a 1-year high of $74.12. The company has a market cap of $76.63 billion, a PE ratio of 18.63, a P/E/G ratio of 0.63 and a beta of 0.34.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 29th. Shareholders of record on Thursday, September 15th will be given a $0.73 dividend. This represents a $2.92 annualized dividend and a yield of 4.78%. The ex-dividend date of this dividend is Wednesday, September 14th. Gilead Sciences’s payout ratio is 89.02%.

Gilead Sciences Profile

(Get Rating)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.

Read More

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILDGet Rating).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.